Table 4 Multivariate analysis of the factors associated with dispensation of celecoxib and rofecoxib versus traditional nonselective NSAIDs
Celecoxib | Rofecoxib | |
|---|---|---|
Age group | ||
75+ | 5.34 (4.96–5.75) | 3.06 (2.83–3.30) |
55 to ≤74 | 3.65 (3.45–3.87) | 2.62 (2.46–2.78) |
18–54 | Reference | Reference |
Female sex | 1.55 (1.47–1.62) | 1.45 (1.38–1.52) |
Income level (lower) | 0.95 (0.88–1.02) | 0.83 (0.77–0.89) |
Prior diagnosis of gastropathy | 1.21 (1.07–1.37) | 1.11 (0.97–1.27) |
Prior gastrointestinal procedures | 1.21 (1.02–1.42) | 0.97 (0.81–1.16) |
Prior dispensation of gastroprotective agents | 1.59 (1.48–1.71) | 1.51 (1.41–1.63) |
Prior referral to gastroenterologist | 1.27 (1.11–1.45) | 1.19 (1.03–1.37) |
Prior history of NSAID use: | ||
Recent, first time | 2.25 (1.99–2.54) | 2.02 (1.79–2.29) |
Recent, chronic | 1.68 (1.52–1.85) | 0.75 (0.68–0.84) |
>1 to 3 months | 1.36 (1.26–1.45) | 0.48 (0.44–0.52) |
>3 to 12 months | 0.85 (0.80–0.91) | 0.81 (0.76–0.87) |
No use in past year | Reference | Reference |
Corticosteroids | 1.11 (1.02–1.20) | 1.20 (1.11–1.31) |
Anticoagulants | 1.61 (1.34–1.94) | 1.48 (1.23–1.78) |
Antidepressants | 1.38 (1.28–1.48) | 1.37 (1.27–1.48) |
Benzodiazepines | 1.18 (1.12–1.25) | 1.15 (1.09–1.22) |
Acetaminophen | 1.39 (1.31–1.48) | 1.37 (1.28–1.45) |
Low-dose ASA | 0.67 (0.62–0.71) | 0.58 (0.54–0.62) |
Chronic Disease Score | ||
10+ | 1.26 (1.11–1.43) | 1.20 (1.06–1.37) |
5–9 | 1.28 (1.19–1.38) | 1.23 (1.14–1.33) |
1–4 | 1.25 (1.17–1.33) | 1.26 (1.18–1.34) |
0 | Reference | Reference |
Physician specialty | 0.96 (0.90–1.03) | 0.83 (0.77–0.89) |
Dosage | ||
High dose | 3.36 (3.15–3.58) | 0.76 (0.70–0.82) |
Low dose | 0.09 (0.09–0.10) | 0.73 (0.69–0.78) |
Standard dose | Reference | Reference |
Time period | ||
January–June | 1.25 (1.16–1.34) | 0.24 (0.22–0.26) |
July–September | 1.09 (1.00–1.19) | 0.93 (0.87–1.01) |
October–December | Reference | Reference |